Related Experiment Video
Updated: Dec 9, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Qingfei Paidu decoction for treating COVID-19: A protocol for a meta-analysis and systematic review of randomized
Yuan Zhang1, Hongyan Xie, Yan Li
1Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Insights
This review synthesizes evidence on Qingfei Paidu Decoction (QFPD) for COVID-19 treatment. It assesses QFPD
Area of Science:
- Integrative Medicine
- Infectious Diseases
- Pharmacology
Background:
- Coronavirus disease 2019 (COVID-19) poses a significant global health threat with no definitive treatment.
- Traditional Chinese Medicine (TCM) has a history of treating acute infectious diseases.
- Qingfei Paidu Decoction (QFPD) is a widely used TCM formula for COVID-19 in China, but evidence on its efficacy and safety requires systematic evaluation.
Purpose of the Study:
- To systematically review and meta-analyze the efficacy and safety of Qingfei Paidu Decoction (QFPD) for treating COVID-19.
- To provide comprehensive evidence on QFPD's clinical effectiveness and safety profile.
Main Methods:
- Systematic literature search of multiple databases (e.g., PubMed, EMBASE, CNKI) for randomized controlled trials (RCTs) published up to May 2020.
- Independent screening, data extraction, and quality assessment of eligible RCTs.
- Meta-analysis of dichotomous (relative risk) and continuous (mean difference/standardized mean difference) data using fixed or random effect models, assessing clinical effectiveness, lung CT improvement, and adverse events.
Main Results:
- The study will synthesize data from selected RCTs to evaluate the effectiveness and safety of QFPD.
- Key outcomes include overall clinical effective rate, improvement in lung CT scans, and incidence of adverse events.
- Secondary outcomes encompass the effective rate of clinical symptoms and treatment duration.
Conclusions:
- This systematic review and meta-analysis aims to provide robust evidence regarding the efficacy and safety of Qingfei Paidu Decoction (QFPD) for COVID-19.
- The findings will inform clinical practice and future research on TCM for COVID-19 management.
Background:
Coronavirus disease 2019 (COVID-19) is one of the infectious diseases that have seriously threatened global public health since its outbreak in 2019. Due to the complicated Pathogenesis, high infectivity and high fatality rate of COVID-19, there is currently no effective treatment for such epidemic disease. Traditional Chinese medicine has a long clinical history for the prevention and treatment of this kind of acute infectious disease. Qingfei Paidu Decoction (QFPD) is widely used in treating COVID-19 in China. However, there is still a lack of comprehensive and systematic evidence on the effectiveness and safety of Qingfei Paidu Decoction.
Methods:
We will search each database from the built-in until May 2020. The English literature mainly searches Cochrane Library, PubMed, EMBASE, and Web of Science, while the Chinese literature comes from CNKI, CBM, VIP, and Wangfang database. Simultaneously we will retrieval clinical registration tests and grey literatures. This study only screen the clinical randomized controlled trials (RCTs) about QFPD for COVID-19 to assess its efficacy and safety. The two researchers worked independently on literature selection, data extraction, and quality assessment. The dichotomous data is represented by relative risk (RR), and the continuous is expressed by mean difference (MD) or standard mean difference (SMD), eventually the data is synthesized using a fixed effect model (FEM) or a random effect model (REM) depending on whether or not heterogeneity exists. Total clinical effective rate, improvement rate of lung CT, adverse events were evaluated as the main outcomes. Effective rate of clinical symptoms, treatment time were secondary outcomes. Finally, meta-analysis was conducted by RevMan software version 5.3.
Results:
The results of our research will be published in a peer-reviewed journal.
Conclusion:
This systematic review aims to provide new evidence of QFPD for COVID-19 in terms of its efficacy and safety.
Prospero Registration Number:
CRD42020200894.
